Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.

Fleischmann R, et al. Lancet. 2017;390(10093):457-468.

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.

Strand V, et al. Arthritis Res Ther. 2015;17:362.

Baricitinib versus placebo or adalimumab in rheumatoid arthritis.

Taylor PC, et al. N Engl J Med. 2017;376(7):652-662.

Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis.

Winthrop K, et al. Arthritis Rheumatol. 2020;72(suppl 10). Abstract 0202.

Long-term safety and effectiveness of upadacitinib or adalimumab in patients with rheumatoid arthritis: results at 72 weeks.

Fleischmann R, et al. Arthritis Rheumatol. 2020;72(suppl 10). Abstract 0212.

Trial of upadacitinib or abatacept in rheumatoid arthritis.

Rubbert-Roth A, et al. N Engl J Med. 2020;383(16):1511-1521.

Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis.

Cohen SB, et al. Ann Rheum Dis. 2020;79(suppl 1):319-320. Abstract THU0197.

Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results.

Combe B, et al. Arthritis Rheumatol. 2020;72(suppl 10). Abstract 0208.

Integrated safety analysis of filgotinib treatment for rheumatoid arthritis from 7 clinical trials.

Genovese MC, et al. Ann Rheum Dis. 2020;79(suppl 1):324-325. Abstract THU0202.

Efficacy and safety of switching jakinibs in rheumatoid arthritis.

Retuerto M, et al. Arthritis Rheumatol. 2020;72(suppl 10). Abstract 0818.

Thromboembolic safety reporting of tofacitinib and baricitinib: an analysis of the WHO VigiBase.

Vallejo-Yagüe E, et al. Drug Saf. 2020;43(9):881-891.

The Impact of Step-Therapy Policies on Patients

Snow J, et al. Xcenda AmerisourceBergen. December 4, 2019.

Treatment delays associated with prior authorization for infusible medications: a cohort study.

Wallace ZS, et al. Arthritis Care Res (Hoboken). 2020;72(11):1543-1549.

‘The Great Debate’: JAK inhibitors vs biologics following methotrexate failure in RA.

Bernard, C. Medicine Matters. ACR 2020 Conference Coverage.

Additional abstracts from 2020 ACR Convergence, All Virtual.

From November 5-9, 2020.

Clinician, Patient, and Caregiver Resources

Coalition of State Rheumatology Association (CSRO) Legislative Map Tool

The CSRO’s legislative map tool provides information about existing and pending step therapy, nonmedical switching, accumulator adjustment program, and uniform prior authorization laws by state and at the federal level.

American College of Rheumatology: Patient and Caregiver Resources

The ACR has produced a library of videos about the impact of rheumatic disease, what to do when diagnosed with rheumatic disease, when to see a rheumatologist, and what patients have to say about their experiences of living with rheumatic disease.

Arthritis Foundation

The Arthritis Foundation provides self-care tools and resources covering treatment options, pain management, diet and exercise, and common comorbidities associated with many different arthritic conditions.

European League Against Rheumatism

EULAR is an organization that represents people with arthritis/rheumatism, health professionals, and scientific societies of rheumatology of all the European nations.

National Institutes of Health (NIH) Health Topics: Rheumatoid Arthritis

A resource from the National Institute of Arthritis and Musculoskeletal and Skin Diseases for people who have rheumatoid arthritis, as well as for their family members, friends, and others who want to find out more about rheumatoid arthritis.